It will change the full ginoom sequence

world The pregnancy predicts radically, and the light of Siddiqui expects. And she said in Wire Last week’s summit. “There is just a huge amount of risks that you can mix from the table.”

SEDIDIQUI is the founder and CEO of OCHID, a biotechnology company that offers Full ginoom examination From the embryos for IVF. By analyzing the DNA of different fetuses before choosing any one to transplantation, orchid says, parents can reduce the risks that their children are affected by genetic conditions. My friend was talking to George Cherish-a pioneer in the genome and a professor of heredity at the Harvard University College of Medicine-at the top of Boston, and exploring the promise and the potential of complete genomic sequence.

and estimated 4 per cent of people around the world have a disease caused by a single genetic mutation. With a fetus examination, “these diseases can be completely avoided completely.” Moreover, nearly half of the world’s population suffers from a chronic disease with at least a genetic foundation. “You can now reduce the genetic component of this danger through these two numbers with two numbers. (You can watch the session in the video below; there is a problem at first with the MIC from Noor Seddiqui, which was fixed on the 6 -minute mark.)

Orchid, which Reference Statistical analysis on the amount of risk reduction that can be achieved through a fetus examination shows that the accurate decrease in relative risks depends on a number of factors. These include, among other things, the spread of the disease, the number of embryos that have been analyzed, and the effect of the genetic variables that have been examined on the possibility of the disease development.

The church is an investor in orchid, and it is believed that the type of fetus inspection it provides is among the most effective medical techniques that have been created at all. The human genome project, the first effort to draw a map for all human genes, costs $ 3 billion, but since, the cost of the genome sequence has decreased significantly. Orchid’s complete genome sequence costs several thousand dollars per fetus. This is “perhaps a return of 10 times on investment,” the church believes. “A large part of our healthcare costs, psychological problems, and family issues can be solved in this way.”

Siddiqui used technology to examine its embryos. The story of her mother, who suffered from adult blindness, shared the adult meters as a result of a genetic contrast in her genome. “Fortunately, all embryos are negative for that,” she said. “But the other thing is very common in most families of South Asia is an incredibly great danger to heart disease and diabetes. This is the other thing that we rely on priority.”

The blindness that Siddique described is monochrome, which means that it was the result of one genetic contrast. Among the well -known individual genes diseases, “95 percent do not have a treatment, much less than a treatment.” But many other cases – such as schizophrenia, bipolar disorder, or heart disease – are multi -genetic, driven by the cumulative effect of many genetic variables. For this, genetic risk degrees can determine the risk of a disease, and can be calculated for adults and fetuses. Orchid fetal tests are looking for both types of disease.